MBX Biosciences Inc. (MBX) said that it has priced its initial public offering of 10.20 million shares of its common stock at $16.00 per share.The company noted that it expects gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses, to be $163.2 million.

MBX生物科学公司（MBX）表示，其首次公开发行1020万股普通股的定价为每股16.00美元。该公司指出，在扣除承销折扣、佣金和发行费用之前，预计此次发行的总收益为1.632亿美元。

In addition, MBX Biosciences has granted the underwriters a 30-day option to buy an additional 1.53 million shares of its common stock at the initial public offering price, less underwriting discounts and commissions.The shares are expected to begin trading on the Nasdaq Global Select Market on September 13, 2024 under the ticker symbol 'MBX.' The offering is expected to close on September 16, 2024.

此外，MBX Biosciences授予承销商30天的期权，以首次公开发行价格（扣除承销折扣和佣金）再购买153万股普通股。预计这些股票将于2024年9月13日在纳斯达克全球精选市场开始交易，股票代码为“MBX”此次发行预计于2024年9月16日结束。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局决定生物技术股